Abstract 983: Design and methodology of LAPIS, an ongoing, phase III trial of neoadjuvant pamrevlumab (pam) with chemotherapy (CT) in patients (pts) with unresectable, locally advanced pancreatic cancer (LAPC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-983
Abstract: Background: LAPC is associated with a median overall survival (OS) of 15-18 mos in contemporary clinical trials. CT is typically the initial treatment, and subsequent surgical resection with curative intent is rare. Pam is a… read more here.
Keywords: methodology; lapc; phase; phase iii ... See more keywords
Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.272
Abstract: 272Background: Curative resection is possible following neoadjuvant treatment for LAPC, yet there is no method to identify patients beforehand who will have a favorable surgical outcome. This study... read more here.
Keywords: surgical outcome; lapc; circulating tumor; using circulating ... See more keywords